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Objectives The objective was to evaluate the systemic ventricular ejection fraction (SVEF) at the time of systemic atrioven-
tricular valve (SAVV) replacement as a predictor of SVEF 1 year after surgery in patients with congenitally cor-
rected transposition of the great arteries (CCTGA).
Background Progressive SAVV regurgitation causes systemic ventricular failure in CCTGA patients, who are commonly re-
ferred late for intervention. Survival after surgery is poor when the pre-operative SVEF is 44%.
Methods We retrospectively reviewed 46 patients (pre-operative SVEF 40% in 27 patients and 40% in 19 patients)
with 2 good-sized ventricles, a morphologically right systemic ventricle, and SAVV regurgitation requiring surgery.
Median follow-up was not different in patients with a pre-operative SVEF 40% (8.8 years) or 40% (7.7 years,
p  0.36).
Results Pre-operative SVEF was the only independent predictor of 1-year post-operative SVEF (p  0.0001). The late
SVEF was preserved (defined as 40%) in 63% of patients who underwent surgery with an SVEF 40% com-
pared with 10.5% of patients who underwent surgery with an SVEF 40%. Pre-operative variables associated
with late mortality were an SVEF 40%, a subpulmonary ventricular systolic pressure 50 mm Hg, atrial fibrilla-
tion, and New York Heart Association functional class III to IV.
Conclusions Post-operative systemic ventricular function after SAVV replacement can be predicted from the pre-operative
SVEF. For best results, operation should be considered at an earlier stage, before the SVEF falls below 40% and
the subpulmonary ventricular systolic pressure rises above 50 mm Hg. (J Am Coll Cardiol 2011;57:2008–17)
© 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.021In congenitally corrected transposition of the great arteries
(CCTGA), atrioventricular and ventriculoarterial discor-
dance maintains the appropriate direction of blood flow.
The morphological right ventricle (RV) supports the sys-
temic circulation and the morphological tricuspid valve is
the systemic atrioventricular valve (SAVV) (1). In up to 70%
of cases, the SAVV is abnormal and may be inferiorly
displaced: the so-called Ebstein’s anomaly of the SAVV
(2,3). It is the presence of an anatomically abnormal SAVV
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2010, accepted November 23, 2010.rather than ventricular dilatation and dysfunction that
predicts the occurrence of regurgitation (3). SAVV regur-
gitation may also occur after closure of a ventricular septal
defect (4). In the series of Prieto et al. (3), SAVV regurgi-
tation was the only independent predictor of death in
CCTGA. In a retrospective cohort, more than 50% of
deceased patients had systemic ventricular failure, associated
with severe SAVV regurgitation in most cases (5).
See page 2018
Beauchesne et al. (6) found that 53% of adult CCTGA
patients are referred late, already suffering from moderate to
severe SAVV regurgitation and ventricular dysfunction for
more than 6 months. In patients referred for SAVV
replacement, 10-year post-operative survival is only 19.5%
when the pre-operative systemic ventricular ejection fraction
(SVEF) is below 44% (7). Survival with CCTGA thus
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May 17, 2011:2008–17 Pre-Operative Ventricular Function in Corrected Transposition of the Great Arteriesappears closely linked to the presence of SAVV regurgita-
tion and systemic ventricular dysfunction. Although it is
often assumed that when the morphological RV functions
as a systemic ventricle it is doomed to fail, failure most
commonly occurs as a result of volume overload from SAVV
regurgitation (3). If this holds true, then timely SAVV
replacement may preserve ventricular function and, ulti-
mately, improve long-term outcomes (3,7,8). This has
been shown for the analogous situation of mitral regur-
gitation and left ventricular ejection fraction (9). The
objectives of this study were: 1) to evaluate the SVEF at
the time of SAVV replacement as a predictor of systemic
ventricular function 1 year after surgery; and 2) to identify
re-operative variables that are associated with post-operative
urvival. The hypothesis is that patients with CCTGA undergo-
ng SAVV replacement with a preserved SVEF (40%) maintain
preserved SVEF in the long term.
ethods
atients. Patients with CCTGA were identified from the
ayo Clinic clinical databases. Inclusion criteria were:
) SAVV regurgitation that required valve replacement
erformed at Mayo Clinic; and 2) a known SVEF at the
ime of SAVV replacement. Patients with pulmonary atresia
r double outlet RV or who had a Fontan or a double-
witch operation were excluded. Patients were grouped
ccording to their SVEF (40% or 40%). The patient
election is outlined in Figure 1. Follow-up was deemed
omplete if an SVEF was measured 1 year after surgery.
he 12 patients who were without SVEF follow-up were
ncluded in the survival analysis.
After a review of records, 41% of patients with a pre-
perative SVEF 40% had not returned for follow-up after
ear 2006 and were not known to be deceased, compared
ith only 11% of patients with a pre-operative SVEF
40%. It was possible that patients with a better systemic
entricular function were doing well and did not perceive
he need to follow up in a tertiary care center such as ours.
o strengthen this follow-up, 11 patients with a pre-
perative SVEF 40% and no follow-up after year 2006
ere surveyed with mailed questionnaires and brief phone
nterviews. Questionnaires were returned by 8 patients, 1
atient was reached by phone, and 2 patients could not be
etraced. The protocol was approved by the Mayo Clinic
nstitutional Review Board.
ata collection. Medical records were retrospectively re-
iewed. A medication was deemed used if taken after
urgical dismissal. Functional status was assessed with the
arnes-Somerville ability index (10), the New York Heart
ssociation (NYHA) functional class, and the functional
erobic capacity. The primary outcomes examined were the
VEF and survival or freedom from heart transplantation
1 year after surgery.
easurement of SVEF. SVEF measurements were ex-racted from reports of echocardiography, angiography, fiRI, or CT angiograms per-
ormed preferentially at Mayo
linic. Selected studies were re-
iewed by 2 investigators (F.P.M.
nd C.A.W.) when information
as deemed insufficient or not
vailable otherwise.
Assessment of SVEF by echo-
ardiography is most frequently
sed at our institution, either by
isual estimate (11) or additional
-mode and 2-dimensional mea-
urements. Priority was given to
RI-derived SVEF, followed by
chocardiography and angiogra-
hy. An SVEF 40% was se-
ected to define preserved sys-
emic ventricular function on the
asis of previous series (7,12).
The pre-operative SVEF mea-
urement closest to surgery was
ecorded. The immediate post-
perative SVEF was measured
ithin 30 days of surgery or dur-
ng the surgical hospitalization,
hichever was longer. The late SVEF was the most recent
easurement, obtained 1 year after surgery.
emodynamic and anatomic assessments. Data were
referentially abstracted from echocardiograms acquired
ith standardized protocols (13,14). A few patients only
ad angiograms, MRI, or CT angiograms. The SAVV
egurgitation was assessed qualitatively as absent, trivial,
ild, moderate, moderate to severe, and severe. Nonsys-
emic (or subpulmonary) atrioventricular valve regurgitant
et systolic velocity by continuous-wave Doppler was used
or noninvasive estimation of the subpulmonary ventricular
ystolic pressure (SPVSP) (15). Ebstein’s anomaly, prolapse,
r dysplastic features defined an abnormal SAVV and were
onfirmed at surgical inspection.
AVV replacement. Standard techniques for cardiopul-
onary bypass were used. Cold potassium, blood cardiople-
ic solution has been used for myocardial protection since
977. Given the poor late results of valvuloplasty, our
nstitution has favored valve replacement in CCTGA pa-
ients (7). The benefits of this approach have also been
eported by others (16).
tatistical analysis. Descriptive statistics for categorical
ariables are reported as frequency and percentage, whereas
ontinuous variables are reported as mean  SD or median
range) as appropriate. Categorical variables were compared
etween patients with pre-operative SVEF 40% and
VEF 40% using chi-square test or Fisher exact test
here appropriate, and continuous variables were com-
ared using 2-sample t test or Wilcoxon rank sum test
here appropriate. Linear regression models were used to
Abbreviations
and Acronyms
CCTGA  congenitally
corrected transposition of
the great arteries
CT  computed
tomography
FAC  functional aerobic
capacity
MRI  magnetic resonance
imaging
NYHA  New York Heart
Association
PVOTO  pulmonary
ventricular outflow tract
obstruction
RV  right ventricle
SAVV  systemic
atrioventricular valve
SPVSP  subpulmonary
ventricular systolic
pressure
SVEF  systemic
ventricular ejection fractionnd univariate and multivariate predictors of late SVEF.
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Pre-Operative Ventricular Function in Corrected Transposition of the Great Arteries May 17, 2011:2008–17The multivariable model considered univariately signifi-
cant variables (p  0.05) with model selection using the
stepwise method (backward and forward methods re-
sulted in the same model). All statistical tests were
2-sided with the alpha level set at 0.05 for statistical
significance. The Kaplan-Meier method was used to
estimate survival statistics. Cox regression models were
used to find the risk factors for late mortality. When
analyzing survival, the optimal cutoff point for the
predictor pre-operative SVEF minimized the log-rank
test p values (17). When analyzing predictors of late
SVEF, we dichotomized preoperative SVEF at 35%,
40%, 45%, and 50% and used the dichotomized SVEF 1
by 1 to identify which variable best fits the linear
regression model. Cutoff points should produce 2 groups
with reasonable sample sizes.
Results
Pre-operative and operative characteristics. There were
46 patients, 5 to 72 years of age with a mean age of 40.8 
14.8 years. Twenty-seven patients had a pre-operative
SVEF 40%, and 19 patients had a pre-operative SVEF
40% (Fig. 1). The pre-operative SVEF was evaluated by
echocardiography (n  43, 93%), by angiography (n  2),
Figure 1 Flow Chart of Patient Selection
Two study groups were established on the basis of a pre-operative SVEF  or 4
included in the survival analysis. CCTGA  congenitally corrected transposition of
SVEF  systemic ventricular ejection fraction.and by MRI (n  1). The groups’ pre-operative character- pstics are outlined in Table 1. Patients who underwent
urgery with an SVEF 40% were younger. Males and
mokers were more common among patients with a pre-
perative SVEF 40%. The functional aerobic capacity,
hen available, was better in patients with a preserved
re-operative SVEF. No patient was in NYHA functional
lass IV heart failure. Heart failure medications were com-
only used, regardless of ventricular function. The SAVV
as abnormal and the mean SPVSP moderately elevated in
ost patients. Prior operations were performed in 5 patients
26.3%) with a pre-operative SVEF40% and in 4 patients
14.8%) with a pre-operative SVEF 45%. The most
ommon operation was ventricular septal defect closure (6 of
6 patients) followed by resection of a subpulmonary mem-
rane and pulmonary atrioventricular valve repair (2 of 46
atients each).
Operative characteristics are presented in Table 2. All
atients underwent SAVV replacement, reflecting our in-
titution’s preference. The first operation was performed in
979. All ball-in-cage prostheses were implanted before
995. There is no correlation between the pre-operative
VEF and the operative year (r  0.173, p  0.1953). One
atient had a previous attempt at SAVV repair. Chordal
reservation was most often performed in patients with a
patients (n  58) with a known vital status after surgical dismissal were
at arteries; preop  pre-operative; SAVV  systemic atrioventricular valve;0%. All
the grere-operative SVEF 40%, likely reflecting a concern to
p centage
ntricula
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May 17, 2011:2008–17 Pre-Operative Ventricular Function in Corrected Transposition of the Great Arteriesmaintain ventricular geometry in these patients. One patient
had a Maze procedure.
Post-operative outcomes. Post-operative outcomes are
outlined in Table 3. Follow-up that included a late SVEF
measurement was available at least until year 2005 for all
but 1 patient, who was followed until year 2002. The
median follow-up was not different between the groups
(Table 3). There was no early mortality. Post-operative
morbidity included a similar occurrence of atrial arrhyth-
mias and reoperation in both groups. Reoperations in-
cluded, in patients with a pre-operative SVEF 40%, 4
repeat SAVV replacements, 4 defibrillator implantations
Pre-Operative CharacteristicsTable 1 Pre-Operative Characteristics
n*
Age at surgery (yrs) 27
Female 27
SVEF (%) 27
Time between SVEF measurement and surgery (days) 27
SAVV regurgitation grade 19
Moderate
Moderate to severe
Severe
Abnormal SAVV 26
Ebstein-like anomaly 26
Subpulmonary ventricular systolic pressure (mm Hg) 24
Mean cardiothoracic ratio 12
Associated anomalies 27
Pulmonary outflow obstruction
Ventricular septal defect
Atrial septal defect
High-grade atrioventricular block
Permanent pacemaker 27
Coronary artery disease 27
Diabetes mellitus 27
Hypertension 27
Current or past smoker 27
Hypercholesterolemia 27
Warnes-Somerville ability index 26
1
2
3
New York Heart Association functional class 26
I
II
III
FAC† (%) 11
Pre-operative atrial fibrillation 27
Medication 27
Angiotensin-converting enzyme inhibitor
Angiotensin receptor blocker
Beta-blocker
Loop diuretic
Spironolactone
Digoxin
Data are mean SD (range), n (%), mean SD, or median (range). p 0.05 denotes a statistically
rotocol or a cardiopulmonary exercise test, the functional aerobic capacity is expressed as a per
FAC  functional aerobic capacity; SAVV  systemic atrioventricular valve; SVEF  systemic ve(3 for secondary prevention and 1 for primary preven-tion), 1 pulmonary atrioventricular valve replacement, 1
pericardial window, 1 delayed sternal closure, 1 re-
exploration for tamponade, and resection, debridement,
and homograft patch repair of a mycotic pseudoaneurysm
of the ascending aorta in 1 patient. In patients with a
pre-operative SVEF 40%, reoperations and re-interventions
included 5 defibrillator implantations (4 for secondary
and 1 for primary prevention, 1 biventricular pacemaker),
2 early re-explorations for bleeding, 2 pulmonary valve
replacements, and 1 pulmonary atrioventricular valve
replacement. The use of heart failure medications was
more common than pre-operatively, regardless of ventric-
EF >40% n* SVEF <40% p Value
16 (5–72) 19 43 13 (21–63) 0.42
19 (70%) 19 4 (21%) 0.001
.2 5.4 19 32.2 4.9 0.001
(1–456) 18 34 (1–120) 0.38
27 0.43
2 (7%) 3 (16%)
8 (30%) 3 (16%)
17 (63%) 13 (68%)
22 (85%) 18 15 (83%) 0.91
15 (58%) 18 9 (50%) 0.61
.0 22.0 15 59.7 31.8 0.20
2 0.09 7 0.56 0.10 0.39
19
9 (33%) 9 (47%) 0.34
7 (26%) 6 (32%) 0.68
10 (37%) 7 (37%) 0.99
9 (33%) 9 (47%) 0.34
5 (19%) 19 7 (37%) 0.16
1 (4%) 18 3 (17%) 0.13
0 (0%) 19 0 (0%)
1 (4%) 19 2 (11%) 0.36
6 (22%) 19 12 (64%) 0.03
3 (11%) 19 3 (16%) 0.64
19 0.35
14 (54%) 14 (74%)
8 (31%) 4 (21%)
4 (15%) 1 (5%)
19 0.68
12 (46%) 11 (58%)
13 (50%) 7 (37%)
1 (4%) 1 (5%)
.9 14.5 13 62.6 18.0 0.002
7 (26%) 19 7 (37%) 0.43
19
19 (70%) 12 (63%) 0.61
3 (11%) 1 (5%) 0.49
5 (19%) 3 (16%) 0.81
11 (41%) 8 (42%) 0.93
1 (4%) 0 (0%) 0.40
9 (33%) 15 (79%) 0.003
ant difference between groups. *Number of patients with available data. †Using a Bruce treadmill
of expected when compared with the predicted value for sex and age.
r ejection fraction.SV
39
46
16
49
0.5
85
significular function. The incidence of ventricular arrhythmias
m
m
cant dif
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Pre-Operative Ventricular Function in Corrected Transposition of the Great Arteries May 17, 2011:2008–17and of pacemaker and defibrillator implantation was
similar in both groups.
Prediction of post-operative SVEF. The SVEF 1 year
after surgery was measured by echocardiography in 45
patients (98%) and by CT angiography in 1 patient. Early
Operative CharacteristicsTable 2 Operative Characteristics
n* S
SAVV replacement 27 2
Type of prosthetic valve 27
Ball-in-cage
Tilting disc 1
Bioprosthesis
Previous SAVV replacement 27
Previous SAVV repair 27
Bypass time (min) 26
Chordal preservation 27
Concomitant procedures 27 1
Atrial septal defect closure
Ventricular septal defect closure
Pulmonary outflow surgery
Aortic valve replacement
Data are n (%) or mean  SD. p  0.05 denotes a statistically signifi
Abbreviations as in Table 1.
Post-Operative OutcomesTable 3 Post-Operative Outcomes
n*
Follow-up (yrs) 27
Vital status
SVEF
Late mortality or cardiac transplantation 27
Late SVEF (%) 27
Early mortality 27
Immediate post-operative SVEF (%) 24
Moderate or more residual SAVV regurgitation 25
Ventricular arrhythmias 27
Sudden death, ventricular fibrillation, or sustained VT
Nonsustained VT or symptomatic PVCs
New-onset atrial arrhythmias 27
Atrial fibrillation
Atrial flutter
Supraventricular tachycardia
Permanent pacing 27
Immediate post-operative
Late 27
Admission for heart failure 27
Warnes-Somerville ability index 1 to 2 27
FAC (%) 16
Reoperation 27
Medication 27
Angiotensin-converting enzyme inhibitor
Angiotensin receptor blocker
Beta-blocker
Loop diuretic
Spironolactone
DigoxinData are median (range), n (%), or mean  SD. p  0.05 denotes a statistically significant difference be
PVC  premature ventricular contraction; VT  ventricular tachycardia; other abbreviations as in Tableand late post-operative SVEF reflected pre-operative
SVEF. The majority of patients (17 of 27 patients, 89.5%)
who underwent surgery with a pre-operative SVEF 40%
aintained an SVEF 40% at late follow-up (Fig. 2). The
ean duration of cardiopulmonary bypass was significantly
40% n* SVEF <40% p Value
0%) 19 19 (100%)
19 0.19
%) 4 (21%)
%) 14 (74%)
%) 1 (5%)
) 19 0 (0%)
) 19 0 (0%) 0.40
53 19 128 42 0.72
%) 19 8 (42%) 0.0322
%) 19 12 (63%) 0.37
%) 5 (26%) 0.81
%) 2 (11%) 0.67
) 2 (11%) 0.95
) 2 (11%) 0.36
ference between groups. *Number of patients with available data.
VEF >40% n* SVEF <40% p Value
19
8 (1.7–24.2) 7.7 (1.7–18.2) 0.36
6 (1.7–24.2) 5.4 (1.0–18.2) 0.15
4 (15%) 19 7 (37%) 0.08
6.0 10.5 19 37.4 11.4 0.001
0 (0%) 19 0 (0%)
0.1 5.7 16 31.9 8.6 0.003
2 (8%) 18 0 (0%) 0.31
7 (26%) 19 10 (52%) 0.06
4 (15%) 6 (21%)
3 (11%) 8 (28%)
14 (52%) 19 10 (53%) 0.95
5 (19%) 6 (32%)
4 (15%) 3 (16%)
3 (11%) 1 (5%)
19
8 (30%) 4 (21%) 0.51
3 (11%) 19 7 (37%) 0.0672
7 (26%) 19 8 (42%) 0.25
25 (93%) 19 17 (89%) 0.27
81 26 14 62 10 0.0192
11 (41%) 19 11 (58%) 0.37
19
23 (85%) 16 (84%) 0.93
7 (26%) 4 (21%) 0.70
15 (56%) 12 (63%) 0.61
15 (56%) 9 (47%) 0.58
1 (4%) 5 (26%) 0.02
16 (59%) 15 (79%) 0.16VEF >
7 (10
4 (15
6 (59
7 (26
0 (0%
1 (4%
123
3 (11
5 (56
8 (30
4 (15
1 (4%
1 (4%S
8.
7.
2
4tween groups. *Number of patients with available data.
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May 17, 2011:2008–17 Pre-Operative Ventricular Function in Corrected Transposition of the Great Arterieslonger in the 10 patients whose SVEF decreased below 40%
after surgery (158  60 min vs. 101  36 min in patients
ho kept a post-operative SVEF 40%, p  0.0058). The
re-operative SVEF was the most significant predictor of
he late post-operative SVEF by multivariate regression
nalysis (estimate 0.83; 0.49 to 1.16; p  0.0001) (Table 4).
Figure 2 Outcome of Post-Operative Ventricular Function Acco
More patients with a preserved pre-operative SVEF have an SVEF 40% at late fol
Univariate and Multivariate Analysis forPredictors of the Late Post-Operat ve SVEFTable 4 Univariate and Multivariate Analysis forPredictors of the Late Post-Operative SVEF
Estimate
95% Confidence
Interval p Value
Univariate analysis
Complex CCTGA* –5.53 –12.38 to 1.32 0.11
Age at surgery –0.11 –0.35 to 0.13 0.38
Pre-operative SVEF 0.83 0.49 to 1.16 0.001
Duration of follow-up 0.0006 –0.0014 to 0.0027 0.56
Paced rhythm –6.42 –13.38 to 0.55 0.07
Abnormal SAVV –5.03 –14.48 to 4.41 0.30
Known coronary artery disease –7.1 –19.4 to 5.2 0.26
Hypertension –2.03 –16.26 to 12.20 0.78
Tobacco use –7.16 –14.15 to –0.17 0.045
Hypercholesterolemia –3.62 –14.01 to 6.77 0.50
Warnes-Somerville ability index
3 9.99 –1.07 to 21.06 0.08
2 –1.53 –9.40 to 6.33 0.70
New York Heart Association
functional class
III 4.63 –12.79 to 22.06 0.60
II 1.31 –5.91 to 8.53 0.72
Pre-operative atrial fibrillation –2.00 –9.63 to 5.61 0.61
Pre-operative use of diuretics –0.63 –7.69 to 6.43 0.86
Concomitant operation with
SAVV replacement
–2.06 –9.20 to 5.09 0.573
Post-operative use of ACEI or ARB 0.24 –23.88 to 24.36 0.99
Post-operative use of beta-blockers –0.052 –7.20 to 7.09 0.99
Post-operative use of
spironolactone
–9.72 –19.78 to 0.34 0.06
Multivariate analysis
Pre-operative SVEF 0.83 0.49 to 1.16 0.0001
p  0.05 denotes statistical significance. *Defined as an associated ventricular septal defect or
pulmonary outflow obstruction.ACEI angiotensin-converting enzyme inhibitors; ARB angiotensin receptor blocker; CCTGA
congenitally corrected transposition of the great arteries; other abbreviations as in Table 1.fter adjusting for it, none of the other variables tested were
ignificant (Table 4).
isk factors for late mortality. The late post-operative
ortality or need for cardiac transplantation was 15% in
atients with a pre-operative SVEF40% and 37% in those
ith a pre-operative SVEF 40% (p  0.08). Kaplan-
eier survival analysis included 58 patients with known
ital status after surgical dismissal (Fig. 1). All but 3 of these
atients had a known vital status until year 2005 or later; 2
atients were followed until year 2001 and 1 until year 2002.
he estimates for 1-, 5-, and 10-year post-operative survival
r freedom from transplantation were 96.5%, 90.6%, and
4.1%, respectively. Variables tested as risk factors for late
ortality or transplantation are listed in Table 5. A higher
pre-operative SVEF was associated with better outcomes
(hazard ratio [HR]: 0.94; 95% confidence interval [CI]:
0.89 to 0.99; p  0.02) (Table 5). Patients with a pre-
operative SVEF 40% had a significantly better post-
operative survival or freedom from transplantation (p 
.02) (Fig. 3). A pre-operative SPVSP 50 mm Hg
redicted post-operative mortality or transplantation (HR:
.42; 95% CI: 1.44 to 28.53; p  0.02) (Fig. 4). A high
PVSP may reflect either a pulmonary ventricular outflow
ract obstruction (PVOTO) or pulmonary hypertension; 13
atients had both a pre-operative SPVSP 50 mm Hg and
history of PVOTO. Their 10-year post-operative survival
as 41.2% compared with 71.4% in patients without these
haracteristics. A history of PVOTO alone did not substan-
ially impair late survival (HR 0.98; 95% CI: 0.38 to 2.53;
 0.96). Any pre-operative atrial fibrillation or NYHA
functional class III to IV was also associated with post-
operative mortality or transplantation (Table 5). The post-
operative use of a beta-blocker (HR: 0.29; 95% CI: 0.11 to
0.77; p  0.01) and a higher early post-operative SVEF
(HR: 0.92; 95% CI: 0.85 to 0.98; p  0.02) was associated
with a substantially better long-term outcome (Table 5).
Identification of the best pre-operative SVEF threshold.
We tested 4 pre-operative SVEF thresholds (35%, 40%,
45%, and 50%) to predict late SVEF and survival. When
to Pre-Operative SVEF
(1 year). Abbreviations as in Figure 1.rding
low-upanalyzing the pre-operative SVEF as a predictor of post-
2014 Mongeon et al. JACC Vol. 57, No. 20, 2011
Pre-Operative Ventricular Function in Corrected Transposition of the Great Arteries May 17, 2011:2008–17operative survival, a cutoff SVEF of 40% produced the
lowest log-rank test p value. When analyzing the pre-
operative SVEF as a predictor of late SVEF, 40%, 45%, and
50% were not significantly different in predicting late
Univariate Cox Regression Model toPredict Post-Operative Mortality or Need forCar ac Transplantation (  58)
Table 5
Univariat Cox Regression Model to
Predict Post-Operative Mortality or Need for
Cardiac Transplantation (n  58)
Hazard Ratio
95% Confidence
Interval p Value
Pre-operative SVEF 0.94 0.89–0.99 0.02
Complex CCTGA 0.77 0.30–1.97 0.59
Paced rhythm 2.15 0.75–6.13 0.15
Age at surgery 1.02 0.98–1.05 0.35
Abnormal SAVV 0.65 0.18–2.32 0.51
Previous surgical repair 0.95 0.27–3.30 0.88
Known coronary artery disease 4.13 0.88–19.31 0.07
Hypertension 1.44 0.19–10.94 0.72
Tobacco use 1.50 0.58–3.85 0.40
Hypercholesterolemia 0.64 0.08–4.92 0.67
Warnes-Somerville ability index 3 to 4 1.31 0.28–6.24 0.73
New York Heart Association functional
class III to IV
6.37 1.17–34.58 0.03
Pre-operative atrial fibrillation 2.69 1.06–6.84 0.04
Pre-operative use of diuretics 1.50 0.59–3.82 0.40
Concomitant operation with
SAVV replacement
1.39 0.49–3.93 0.53
Post-operative use of beta-blockers 0.29 0.11–0.77 0.01
Post-operative use of spironolactone 0.81 0.18–3.56 0.78
Pre-operative SPVSP 1.02 1.00–1.04 0.01
Pre-operative FAC 0.98 0.94–1.02 0.37
p  0.05 denotes statistical significance. *Defined as an associated ventricular septal defect or
pulmonary outflow obstruction.
CCTGA  complex congenitally corrected transposition of the great arteries; SPVSP  subpul-
monary ventricular systolic pressure; other abbreviations as in Table 1.
Figure 3 Survival After SAVV Replacement in CCTGA Patients
More CCTGA patients who underwent surgery with an SVEF 40% remain free of dSVEF. However, there were only 8 patients with pre-
operative SVEF 50%.
Discussion
Summary of results. Our study included patients with
CCTGA, 2 good-sized ventricles, a systemic RV, and
SAVV regurgitation requiring valve replacement. Most
patients were referred in adulthood. The pre-operative
SVEF was the only determinant of long-term SVEF, which
was mostly preserved if SAVV replacement was performed
with an SVEF40%. Pre-operative variables that predicted
late mortality or cardiac transplantation include SVEF,
SPVSP, NYHA functional class III to IV, and atrial
fibrillation.
SAVV regurgitation and ventricular dysfunction. As pa-
tients with CCTGA age, their often abnormal SAVV
(Table 1) becomes regurgitant (3). The systemic RV is
intolerant to volume overload, and its performance eventu-
ally decreases (8,18,19). Valvular and ventricular dysfunc-
tions then participate in a vicious cycle leading to further
systemic ventricular dysfunction and failure (20). Other
causes of failure of the systemic RV include mismatch in
oxygen supply and demand, associated defects, prior intra-
cardiac operations, arrhythmias, and pacemaker implanta-
tion (1,2,19). However, CCTGA patients can maintain
good systemic ventricular function and survive beyond the
6th decade in the absence of hemodynamic lesions (21,22).
One patient in our series who was 71 years old at the time
of SAVV replacement and had a pre-operative SVEF of
42% still has an SVEF of 48% at age 86 years, some 15 years
after initial operation. If the regurgitation is severe, timely
valve replacement is indicated to prevent further RV failure.
rding to Pre-Operative SVEF
r cardiac transplantation at follow-up. Abbreviations as in Figure 1.Acco
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operative SVEF was the only independent predictor of late
ventricular function. SAVV replacement did not improve
SVEF in patients with a pre-operative SVEF 40%
(Fig. 2). A subset of patients with a pre-operative SVEF
40% developed ventricular dysfunction after SAVV re-
placement. The duration of cardiopulmonary bypass was
substantially longer in these patients, which may have
influenced ventricular function. It is also possible that
SAVV replacement failed to halt an already established
progressive ventricular dysfunction in these patients. The
median pre-operative SVEF in these patients was 42%
(range 40% to 48%). Operation at an even earlier stage may
be required to truly preserve SVEF.
A paced rhythm did not predict late SVEF or post-
operative mortality. Cardiac resynchronization therapy may
improve the hemodynamics of the failing systemic RV
(23,24), but is technically challenging (24,25).
Post-operative survival. In our study, the 10-year post-
operative survival or freedom from cardiac transplantation
was 64.1%. An SAVV replacement may be only moderately
successful at improving survival because it was performed
too late (6). In the series by van Son et al. (7) from our
institution, all patients with pre-operative SVEF 44%
were alive at 10 years follow-up. Our results suggest that, to
improve survival, SAVV replacement should be performed
with a pre-operative SVEF 40% (Fig. 3). Patients who
underwent surgery with an SVEF 50% were underrepre-
sented in the survival analysis (10 of 58 patients) and may
have had an even better outcome.
Pre-operative atrial fibrillation, either paroxysmal or sus-
Figure 4 Survival After SAVV Replacement in CCTGA Patients
Fewer patients remain free of death or cardiac transplantation at follow-up with a
PVOTO  pulmonary ventricular outflow tract obstruction; SPVSP  subpulmonarytained, was associated with post-operative mortality or needfor cardiac transplantation. Atrial fibrillation likely reflects
more advanced sequelae of SAVV regurgitation on the atria.
In the absence of other surgical indications, we propose that
patients with atrial fibrillation be considered for earlier
operation, which would include a Maze procedure.
We observed a very significant association between the
pre-operative SPVSP and long-term mortality or need for
transplantation. Consequently, outcomes may be improved
if a high SPVSP is avoided before SAVV replacement.
Patients with both PVOTO and high SPVSP have poorer
outcomes and should be closely followed. A history of
PVOTO alone did not influence the late survival or need for
cardiac transplantation.
In a univariate analysis, the post-operative use of beta-
blockers was associated with better survival or freedom from
transplantation. Among 27 patients taking beta-blockers
post-operatively, 63% had atrial arrhythmias and 40.7% had
ventricular arrhythmias, compared with 26.3% and 31.6%,
respectively, in patients not taking beta-blockers. Beta-
blockers did not improve outcomes in a randomized trial
that included pediatric patients with systemic right ventric-
ular dysfunction (26) and must be used cautiously in
CCTGA patients, as they may precipitate atrioventricular
block.
We cannot comment on the outcome of SAVV repair
because all our patients underwent SAVV replacement.
SAVV repairs have had disappointing intermediate and late
results (16).
Evaluation of systemic right ventricular function. Chal-
lenges exist with the evaluation of the systemic right
ventricular performance and relate to the chosen modality
rding to Pre-Operative SPVSP
rative SPVSP 50 mm Hg (p  0.012).
ular systolic pressure; other abbreviations as in Figure 1.Acco
pre-ope
ventricand criteria. In this study, echocardiographic assessment of
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ography in patients with CCTGA can be challenging due to
dextrocardia and the requirements for unusual imaging
planes (1). A visual estimate of SVEF relies heavily on
experience and may in fact reflect a qualitative appreciation.
Currently used normal values for SVEF are derived from
small studies using radionuclide ventriculography (12,21).
Angiography has also been used (18). Experience has shown
that echocardiography can underestimate SAVV regurgita-
tion in this setting, and we recommend consideration of
angiography when the ventricular function declines and the
cardiac silhouette enlarges without explanation (6). MRI
holds promise in the evaluation of the RV (27).
The criteria for ventricular dysfunction have also been
questioned (20). We identified that in this cohort, an SVEF
of 40% best predicts both survival and late systemic ventric-
ular function. The justification for choosing the lower
threshold is that relatively few CCTGA patients present
with a normal SVEF (6). Therefore, an SVEF threshold
that discriminates between patients with a mildly depressed
to normal SVEF (40%) and a moderately or severely
depressed SVEF (40%) is more likely to be useful in
clinical practice. Ejection fraction depends on pre-load and
afterload and may overestimate ventricular function with
SAVV regurgitation. Other potential criteria are the dP/dt
(20), the index of myocardial performance (28), and the
response of SVEF to exercise (12).
Timing of surgery. Lundstrom et al. (8) proposed opera-
tion on asymptomatic or barely symptomatic patients with
CCTGA and cardiac enlargement due to systemic ventric-
ular volume overload. Two surgical approaches can be
envisioned on the basis of the age of the patient at
presentation. A classical approach consisting of early repair
of lesions that overload the systemic RV appears well suited
for older patients, as in our cohort. We propose to operate
in a timely manner to keep the SVEF 40%. For patients
presenting in early childhood, an anatomic repair, the
double-switch operation, has yielded promising results (29).
Adults, however, are much less likely to achieve anatomic
repair (30), and patients with SAVV regurgitation have a
poorer outcome (31). Whether an early double-switch
operation confers long-term benefits over a classical strategy
remains unknown.
Study limitations. Our study is retrospective. The small
number of patients and events (11 deaths) confined us to a
univariate analysis for identifying risk factors for late mor-
tality. The small sample size also makes the multiple
regression solution unstable. Our findings may not apply to
all practices because our institution benefits from experience
in congenital cardiology and cardiac surgery. The SVEF was
predominantly estimated by echocardiography, and we as-
sumed that SVEFs from multiple modalities were compa-
rable. SVEF is dependent on the loading conditions of the
ventricle and may not be the optimal criterion for ventricular
function. Follow-up appeared more scrupulous in patients
with systemic ventricular dysfunction, and thus events mayhave been missed in patients with better ventricular func-
tion. Our cohort does not allow us to evaluate the effects of
cardiac resynchronization therapy and the Maze procedure
in CCTGA patients.
Conclusions
More CCTGA patients undergoing SAVV replacement
survive or remain free of cardiac transplantation with a
pre-operative SVEF 40%. Long-term preservation of
systemic ventricular function is also more likely with a
pre-operative SVEF 40%. Any pre-operative atrial fi-
brillation and an SPVSP 50 mm Hg are risks factors for
late mortality or cardiac transplantation. Patients with
CCTGA should be scrutinized for the presence of SAVV
regurgitation, systemic ventricular dysfunction, and a
high SPVSP. Consideration should be given to SAVV
replacement before the SVEF falls below 40% or the
SPVSP rises above 50 mm Hg.
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